Rectal bleeding and diarrhea caused by bortezomib-induced colitis

Rincón, O Nogales; Madrigal, Alain Huerta; Rodríguez, B Merino; Asanza, C González; Arregui, E. Cos; Fernández-Pacheco, P. Menchén

doi:10.1016/j.gastrohep.2010.05.009

Cited by 6 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, several cases of colitis were reported after taking bortezomib, an inhibitor of the 26S proteasome. 46,47 Functional pathway analysis of the EoC transcriptome also showed evidence of increased apoptosis in agreement with an increased number of apoptotic (cleaved caspase-3) cells in EoC colonic biopsies. Positive regulation of apoptosis could slow down epithelial turnover and proliferation in colonic tissue, leading to impaired intestinal barrier function and facilitating inflammatory processes.…”

Section: Discussionmentioning

confidence: 67%

Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 67%

Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study

et al. 2022

View full text Add to dashboard Cite

“…reported a patient with lgD MM presented with bloody diarrhea during bortezomib treatment. 4 After treatment change, his symptoms improved. 4 Guerrini et al.…”

Section: Discussionmentioning

confidence: 97%

“…4 After treatment change, his symptoms improved. 4 Guerrini et al. recently reported lenalidomide-related bloody diarrhea in a patient with MM.…”

Section: Discussionmentioning

confidence: 97%

A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

Batgi

Dal

Merdin

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Multiple myeloma is a malignant neoplasm of plasma cells. Lenalidomide-dexamethasone treatment is a common treatment regimen used in refractory multiple myeloma. Case report We describe the case of a 58-year-old male multiple myeloma patient with a history of relapse after six months of autologous stem cell transplantation. The patient had nausea and bloody diarrhea developed during lenalidomide treatment. Management and outcome: Computed tomography showed diffuse marked edematous thickness in the wall of colonic, hepatic and splenic flexure, transverse colon, descending colon and sigmoid colon. Colonoscopic observation revealed highly granular, hyperemic and fragile mucosa. Colon biopsy was consistent with ischemic colitis. Lenalidomide treatment was discontinued. One month later, colon findings were detected as normalized through a colonoscopy. Discussion Risk of developing ischemic colitis should be kept in mind in patients receiving lenalidomide which should be discontinued in cases with severe bloody diarrhea of unknown origin.

show abstract

“…The pathogenesis of diarrhea caused by bortezomib is not yet clear. It was believed that this proteasome inhibitor did not cause mucosal damage, but a recent report has described mucositis in the colon of patients under bortezomib treatment ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide

Castro

Neto

Atalla

et al. 2016

Braz J Med Biol Res

View full text Add to dashboard Cite

In order to evaluate the main adverse effects of drug protocols using bortezomib and/or thalidomide for the treatment of multiple myeloma, we conducted a prospective study. Data were collected through interviews, clinical observation, and from hospital records. A total of 59 patients were included. There was a predominance of females, 36 (61%) vs 23 (39%) males, and of whites, 49 (83.1%) vs 10 (16.9%) blacks. Age ranged from 40 to 94 years, with a median of 65 years (SD=11.6). Regarding staging at diagnosis, 27 (45.7%) patients were in stage III-A, with 12 (20.3%) patients having serum creatinine ≥2 mg/dL. The main adverse effects in the bortezomib treatment group (n=40) were: neutropenia (42.5%), diarrhea (47.5%), and peripheral neuropathy in 60% of cases, with no difference between the iv (n=26) and sc (n=14) administration routes (P=0.343). In the group treated with thalidomide (n=19), 31.6% had neutropenia, 47.4% constipation, and 68.4% peripheral neuropathy. Neutropenia was associated with the use of alkylating agents (P=0.038). Of the 3 patients who received bortezomib in combination with thalidomide, only 1 presented peripheral neuropathy (33.3%). Peripheral neuropathy was the main adverse effect of the protocols that used bortezomib or thalidomide, with a higher risk of neutropenia in those using alkylating agents. Improving the identification of adverse effects is critical in multiple myeloma patient care, as the patient shows improvements during treatment, and requires a rational and safe use of medicines.

show abstract

Rectal bleeding and diarrhea caused by bortezomib-induced colitis

Cited by 6 publications

References 2 publications

Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study

Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study

A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide

Contact Info

Product

Resources

About